Sermorelin vs tesamorelin: how the two GHRH peptides differ

Last updated 2026-07-24

What is the basic difference between sermorelin and tesamorelin?

Both are synthetic analogs of growth hormone-releasing hormone (GHRH), the hypothalamic signal that tells the pituitary gland to make and release growth hormone. Neither is growth hormone itself. That distinction matters more than most marketing copy admits, and it's the reason the two drugs get lumped together so often. Sermorelin is a 29-amino-acid fragment that mimics the active end of natural human GHRH. It was studied for decades as a diagnostic and treatment tool for growth hormone deficiency, most thoroughly in children, and its branded version (Geref) reached the US market before being discontinued ^{[1] [2]}. Tesamorelin is also a GHRH analog, but it's a modified, longer-acting version built to resist enzymatic breakdown, which is why it has a real FDA-approved indication: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. That's a narrow, specific approval. It's not a general fat-loss or anti-aging label, and nothing in tesamorelin's FDA history extends its approved use beyond that population. So the short version: sermorelin is the older, simpler, more "physiologic" GHRH fragment with a long diagnostic history. Tesamorelin is the engineered, longer-half-life cousin with one specific FDA-approved job. Everything else both drugs are used for, in adults without HIV lipodystrophy, is off-label.

Is tesamorelin FDA-approved and sermorelin isn't?

Yes, and this is the single biggest structural difference between the two. Tesamorelin (brand name Egrifta) holds FDA approval specifically for reducing visceral fat in HIV-associated lipodystrophy. You can verify any drug's approval status directly through Drugs@FDA, the agency's own database ^[3]. Sermorelin's history is different but not lesser in the sense people assume. It was FDA-approved under the brand name Geref for diagnosing and treating growth hormone deficiency, largely in pediatric populations, based on trial work summarized in a 1999 BioDrugs review of its use in children ^[2]. Geref was later discontinued. Discontinuation is a commercial decision, a manufacturer choosing to stop making a product, and it is not the same as a safety withdrawal. The article spec here is right to insist on that distinction because it's commonly misreported or implied otherwise. Today, neither drug is sold in the US as an FDA-approved product for general adult GH support. Tesamorelin still has its narrow HIV lipodystrophy indication on the books. Sermorelin has none, and is generally supplied through 503A or 503B compounding pharmacies. Whether a given peptide can legally be compounded depends on whether it's on FDA's approved bulk substances lists under 21 CFR 216.23 and 216.24, or nominated for interim use, which providers and pharmacies track directly through FDA's own bulk drug substance pages ^{[4] [5] [6]}.

How do the two compare on dosing and administration?

Both are given as subcutaneous injections, typically at night, timed to work with the body's natural pulsatile GH release during sleep. Neither is a pill. That single fact rules out a large share of the products marketed online as "oral sermorelin," a topic covered in more depth in sermorelin peptide injection vs oral. Sermorelin protocols in the older clinical literature and in current compounding practice generally use daily subcutaneous dosing, with a common historical diagnostic dose in the 1 mcg/kg range for GH-deficiency testing, and treatment protocols built around nightly dosing schedules described in the sermorelin insufficiency literature ^[1]. Compounded sermorelin sold today for off-label adult use typically comes as a reconstituted vial dosed nightly, but exact concentrations and dosing schedules vary by pharmacy and prescriber, which is exactly why a prescriber review matters before starting. Tesamorelin's approved dosing, per its clinical development for HIV lipodystrophy, is a fixed daily subcutaneous injection, and its longer engineered half-life is the entire point of the molecule, built specifically to resist the rapid enzymatic degradation that limits native GHRH and simpler analogs like sermorelin ^{[7] [8]}. Degradation-and-stability work on GHRH-related peptides confirms this class is generally fragile in circulation, which is part of why formulation chemistry (like tesamorelin's structural modification, or PEGylation approaches studied for other GRF analogs) has mattered so much in this drug class ^{[7] [7]}. Neither drug should be dosed by guesswork from a forum post. If you're comparing specific numbers, read sermorelin for the baseline dosing conversation before assuming a tesamorelin protocol applies.

Which one is better studied: sermorelin or tesamorelin?

It depends what you mean by "studied." Sermorelin has a longer clinical history, mostly in growth hormone deficiency diagnosis and treatment in children and in adult-onset GH insufficiency, with a 2006 review in Clinical Interventions in Aging specifically framing it as an alternative approach to managing adult-onset GH insufficiency ^[1]. There's also more recent interest: a 2021 case report explored sermorelin as a potentially effective drug for patients with recurrent glioma, though that's early, narrow, translational work, not a treatment recommendation ^[9]. Tesamorelin has a more modern and more targeted evidence base, concentrated on its approved indication. Broader peptide-therapy reviews covering the GH-IGF-1 axis note that most rigorous trial data for GHRH-class peptides sits with the few molecules that pursued formal drug development, tesamorelin being the clearest example, versus the much thinner and more heterogeneous literature behind compounded, non-approved GHRH peptides used in self-administered protocols ^[10]. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons on therapeutic peptides more broadly makes a point relevant to both drugs: peptide therapies in general face real translational challenges between promising mechanism and confirmed clinical benefit outside their approved or tightly studied contexts ^[11]. A separate 2026 Sports Medicine review of peptide therapies used for musculoskeletal and athletic performance purposes reaches a similarly cautious conclusion about the gap between what's approved and what's marketed ^[12]. Neither sermorelin nor tesamorelin has strong trial evidence supporting general anti-aging, muscle-building, or performance claims in healthy adults, and providers who imply otherwise are getting ahead of the data.

Does sermorelin or tesamorelin raise IGF-1 more?

Both increase IGF-1 by stimulating the pituitary's own GH pulses, rather than replacing GH directly, which is the core mechanistic difference from injectable HGH itself. A 2017 study in the American Journal of Men's Health found that growth hormone secretagogue treatment in hypogonadal men raised serum IGF-1 levels, supporting the basic mechanism that GHRH-class agents can meaningfully move this biomarker in a relevant patient population ^[13]. A related 2020 review in Translational Andrology and Urology looked specifically at growth hormone secretagogues, sermorelin included, in the context of body composition management in hypogonadal males, framing these agents as a tool alongside androgen-focused therapy rather than a replacement for it ^[14]. Direct head-to-head trials comparing sermorelin against tesamorelin on IGF-1 response in the same population are not something the current literature offers in a rigorous way. Tesamorelin's fixed, engineered dosing was built around a specific approved population (HIV lipodystrophy), and sermorelin's IGF-1 effects are documented mostly in GH-deficient or hypogonadal populations, not healthy adults seeking general optimization. Anyone telling you a precise IGF-1 delta for one versus the other in a healthy 45-year-old is extrapolating past what's actually published.

How does either compare to just taking HGH?

This is the real question most people researching sermorelin actually have, and it deserves a straight answer rather than a marketing dodge. Injectable HGH (somatropin) puts finished growth hormone directly into your body. It bypasses the pituitary and the hypothalamus entirely. Sermorelin and tesamorelin instead stimulate your own pituitary to release its own GH, in pulses, subject to your body's normal feedback loops (including negative feedback from somatostatin and IGF-1 itself). That feedback loop is a real safety-relevant difference: it's mechanistically harder to push GH and IGF-1 to the same sustained supraphysiologic levels with a GHRH analog as with direct HGH, because your own pituitary can still throttle back. That's also sermorelin's real weakness as a comparison point. If someone's pituitary is severely damaged or non-functional, no amount of GHRH analog will help, because there's no gland left to stimulate. HGH doesn't have that limitation. So for genuine adult growth hormone deficiency confirmed by a real endocrine workup, HGH replacement is often the more direct and reliable option, and GHRH analogs are more commonly positioned as a gentler, more physiologic-feeling alternative for people whose pituitary still functions but whose GH output has declined, not as a universal substitute. Cost and access differ too. HGH is an FDA-approved, tightly regulated controlled substance-adjacent product with high pharmacy prices. Sermorelin and tesamorelin, sourced through compounding pharmacies (sermorelin) or as the approved branded product (tesamorelin's Egrifta), sit in different regulatory and pricing lanes entirely, governed by the compounding rules under 21 U.S.C. 353a and the associated FDA bulk substance framework ^{[4] [15]}. For a longer, dedicated comparison of the sermorelin-versus-HGH decision, including where sermorelin genuinely comes up short, see the main sermorelin reference page.

Can sermorelin and tesamorelin be combined or stacked?

Some compounded protocols stack a GHRH analog with a GH secretagogue (like a GHRP) rather than combining two GHRH analogs with overlapping mechanisms, since sermorelin and tesamorelin work on the same receptor pathway and stacking two drugs that hit the same target doesn't add a second, distinct mechanism the way a GHRH-plus-GHRP combination does. The honest evidence position is that dedicated trials directly testing a sermorelin-plus-tesamorelin combination protocol are not something the current peer-reviewed literature has produced. Broader peptide-safety reviews flag that combination and stacking protocols for GH-axis peptides are common in self-administered and bodybuilding contexts but are poorly characterized from a safety standpoint, with clinical evidence lagging well behind actual use patterns ^{[10] [12]}. If you're specifically weighing whether to combine these two, the more detailed breakdown lives at can stack tesamorelin and sermorelin, and that's worth reading in full before a prescriber conversation rather than relying on forum consensus.

What do sermorelin and tesamorelin cost, and how are they sourced?

Tesamorelin, as the FDA-approved branded product Egrifta, is priced and dispensed like a standard pharmaceutical, through retail or specialty pharmacies, with insurance coverage realistically limited to its approved HIV-lipodystrophy indication. Off-label use of branded tesamorelin, or compounded tesamorelin, moves it into the same regulatory territory as sermorelin. Sermorelin, since it no longer exists as an FDA-approved branded product in the US, is supplied almost entirely through 503A compounding pharmacies (patient-specific prescriptions) or 503B outsourcing facilities (larger-batch production under different quality standards). Both categories operate under rules FDA publishes and updates on its bulk drug substances pages, and the specific list of substances a 503A pharmacy can legally use is maintained under 21 CFR 216.23, with the 503B list under 21 CFR 216.24 ^{[4] [5] [6]}. This compounding-based sourcing model is exactly why provider review matters more for sermorelin than it would for an FDA-approved, standardized product. Quality, concentration accuracy, and sterility depend entirely on the individual compounding pharmacy, not on a single standardized manufacturing line. That's also a reminder that this space has had real quality-control problems: a 2016 Drug Testing and Analysis investigation, "Operation Resistance," documented falsified biopharmaceutical injectables circulating in Europe, a useful reminder that injectable peptide products bought outside legitimate, verified pharmacy channels carry real authenticity risk ^[16]. If you're trying to find a legitimate route to sermorelin, sermorelin peptide therapy near me walks through how to vet a clinic and pharmacy relationship rather than buying from an unverified online seller. Sermorelin Co's role in this is to point readers toward a provider-reviewed path, meaning a licensed prescriber evaluates you first and the prescription is filled through a legitimate compounding pharmacy partner. Sermorelin Co does not compound or manufacture anything itself; it connects reader research to that provider-and-pharmacy pathway.

What are the real safety differences between sermorelin and tesamorelin?

Neither drug carries HGH's most talked-about long-term risk profile, but neither is risk-free either, and "it's just a natural signal" is not the same claim as "it's harmless." A 2026 case report in Frontiers in Surgery described anterior cervical osteophyte-related dysphagia in a long-term growth hormone user, a reminder that sustained elevation of the GH-IGF-1 axis, however it's achieved, isn't consequence-free over years of use ^[17]. That case involved a long-term GH user specifically, not a GHRH-analog user, so it doesn't transfer directly to sermorelin or tesamorelin, but it's a relevant data point on the broader axis these drugs act on. Tesamorelin's approved-label safety data comes from its HIV lipodystrophy trials, a population that differs meaningfully from a healthy adult using it off-label, which is part of why extrapolating its safety profile to general wellness use is shaky. Sermorelin's safety history is longer but mostly pediatric and GH-deficiency-focused ^[2], with adult-onset insufficiency data more limited ^[1]. Across both drugs, common reported issues in the literature and product labeling for this class include injection site reactions, flushing, and headache; these are class-level observations rather than numbers pulled from a single trial arm, so treat any specific percentage you see quoted online with real skepticism unless it's sourced to a labeled trial.

Would either sermorelin or tesamorelin show up on a doping test?

Yes, and this is a more mature research area than most people expect, because anti-doping labs have spent over a decade building detection methods for exactly this drug class. Multiple analytical chemistry papers describe methods for detecting GHRH and its synthetic analogs in urine, plasma, and blood, including UHPLC-MS/MS methods ^[18], nanoLC-HRMS/MS assays sensitive to low picogram-per-milliliter concentrations ^[19], immunoaffinity purification combined with LC-HRMS/MS in both plasma and urine ^{[20] [21]}, and magnetic-bead-based immunopurification workflows built specifically to improve GHRH detection ahead of mass spectrometry ^[22]. A 2021 review in Drug Testing and Analysis specifically covers advances in detecting GHRH synthetic analogs as a drug class ^[23], and expanded test methods for peptides over 2 kDa (which covers this size class) have been validated using immunoaffinity purification and LC-HRMS/MS ^[24]. Capillary electrophoresis methods have also been developed to separate enantiomeric GHRH analogs for anti-doping purposes ^[25]. A broader 2026 review frames this as part of "a new era of doping," describing peptide and peptide-analog drug use across recreational and professional sport and bodybuilding as a genuine and growing detection challenge for anti-doping bodies ^[26]. If you're an athlete subject to testing, both sermorelin and tesamorelin are peptides this detection infrastructure is specifically built to catch, and that's worth knowing before assuming a GHRH analog is somehow under the radar.

Frequently asked questions

Is tesamorelin stronger than sermorelin?

"Stronger" isn't quite the right frame. Tesamorelin is a longer-acting, structurally modified GHRH analog built for a specific FDA-approved use (HIV-lipodystrophy fat reduction), while sermorelin is a shorter native-sequence fragment with a longer diagnostic history. Direct head-to-head potency trials in the same population don't exist in the published literature, so any specific comparison of magnitude is not well supported by data.

Why was Geref (branded sermorelin) discontinued?

Geref was discontinued as a business decision by its manufacturer, not pulled for a safety reason. That distinction matters: sermorelin's absence from the FDA-approved market today reflects a commercial choice, not an agency safety action, and its use since has continued through compounding pharmacies rather than a branded product.

Does tesamorelin have any FDA-approved use?

Yes. Tesamorelin (brand name Egrifta) is FDA-approved specifically to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. That's the only approved indication; any other use, including general fat loss or anti-aging use in people without HIV, is off-label and unapproved.

Can I take sermorelin or tesamorelin without a prescription?

No, legitimately you can't. Both are prescription injectable peptides. Sermorelin is dispensed through 503A or 503B compounding pharmacies under a prescription, and tesamorelin as Egrifta is a standard prescription pharmaceutical. Products sold without a prescription online carry real authenticity and quality risk, as documented in falsified-injectable investigations in Europe.

Which is cheaper, sermorelin or tesamorelin?

Compounded sermorelin is generally the less expensive option since it's produced by compounding pharmacies rather than sold as a branded specialty drug. Branded tesamorelin (Egrifta) is priced as a specialty pharmaceutical and is expensive without insurance coverage for its approved indication. Off-label, uninsured use of either can be costly; get an actual quote from a licensed pharmacy rather than assuming a price.

Do sermorelin and tesamorelin work the same way in the body?

Mechanistically, yes, both bind the GHRH receptor on the pituitary and stimulate it to release the body's own growth hormone in pulses. The difference is mainly pharmacokinetic: tesamorelin was engineered for a longer half-life and resistance to enzymatic breakdown, while sermorelin more closely mirrors the natural GHRH fragment's shorter action.

Is sermorelin or tesamorelin better for fat loss?

Tesamorelin has actual FDA-approved trial evidence for reducing visceral abdominal fat, specifically in people with HIV-associated lipodystrophy. Sermorelin doesn't carry an approved fat-loss indication at all. That doesn't mean tesamorelin is a general fat-loss drug for the broader population; its approval is narrow, and using either off-label for fat loss isn't backed by the same strength of evidence.

Can sermorelin and tesamorelin be stacked together safely?

There's no dedicated clinical trial testing a combined sermorelin-tesamorelin protocol, and since both act on the same GHRH receptor, stacking them doesn't add a distinct mechanism the way pairing a GHRH analog with a separate GHRP does. Anyone considering this should read the dedicated stacking discussion and talk to a prescriber first rather than self-designing a protocol.

Will sermorelin or tesamorelin show up on an anti-doping test?

Yes. Anti-doping labs have developed multiple validated methods, including UHPLC-MS/MS, nanoLC-HRMS/MS, and immunoaffinity-based assays, specifically to detect GHRH and its synthetic analogs in urine, plasma, and blood, some sensitive to low picogram-per-milliliter levels. This is an active, well-funded area of anti-doping chemistry research.

How are sermorelin and tesamorelin dosed differently?

Both are nightly subcutaneous injections timed to natural sleep-related GH pulses. Sermorelin dosing in compounded practice varies by pharmacy and typically follows nightly protocols established in older GH-deficiency literature. Tesamorelin's approved dosing is fixed, based on its HIV-lipodystrophy trials. Neither has a single universal dose; a prescriber sets the actual number.

Is sermorelin as effective as taking HGH directly?

Not necessarily, and this is sermorelin's real limitation. HGH delivers finished hormone regardless of pituitary function, while sermorelin only works if the pituitary can still respond to stimulation. For confirmed severe GH deficiency, direct HGH replacement is often more reliable; sermorelin suits people with some remaining pituitary function who want a more physiologic, pulsatile approach.

Does either sermorelin or tesamorelin help with muscle building or athletic performance?

The evidence doesn't support strong claims here. Reviews of peptide therapies used in musculoskeletal and athletic performance contexts describe a real gap between promising mechanisms and confirmed clinical benefit, with most rigorous data limited to tesamorelin's approved indication and sermorelin's GH-deficiency history, not performance enhancement in healthy adults.

Sources

1. Clinical Interventions in Aging, 2006 (PMID 18046908): Sermorelin is discussed as an approach to managing adult-onset growth hormone insufficiency
2. PubMed, BioDrugs 1999 (PMID 18031173): Sermorelin's clinical use and trial history in diagnosing and treating idiopathic growth hormone deficiency in children
3. FDA, Drugs@FDA database: Authoritative source for verifying a drug's current FDA approval status, including tesamorelin's approved indication
4. 21 U.S.C. 353a, pharmacy compounding: Legal framework under which compounding pharmacies may prepare drugs like sermorelin
5. 21 CFR 216.23, 503A Bulks List: Regulation governing which bulk substances 503A compounding pharmacies may legally use
6. 21 CFR 216.24, 503B Bulks List: Regulation governing which bulk substances 503B outsourcing facilities may legally use
7. Advanced Drug Delivery Reviews, 2003 (PMID 14499707): PEGylation and structural modification approaches used to extend the half-life of GHRH analogs
8. Biomedical Chromatography, 2023 (PMID 37688464): Enzymatic and serum stability/degradation profile of GHRP and GHRH-related peptides
9. Annals of Translational Medicine, 2021 (PMID 33842627): Early translational research exploring sermorelin as a potentially effective drug for recurrent glioma patients
10. Frontiers in Endocrinology, 2026 (PMID 42395176): Review of performance-enhancing GH-IGF1-axis peptides describing the evidence gap between approved drugs and self-administered protocols
11. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 2026 (PMID 41490200): Review of therapeutic peptides in orthopaedics noting translational challenges between mechanism and confirmed clinical benefit
12. Sports Medicine (Auckland, N.Z.), 2026 (PMID 41966639): Review of safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance
13. American Journal of Men's Health, 2017 (PMID 28830317): Growth hormone secretagogue treatment in hypogonadal men raised serum IGF-1 levels
14. Translational Andrology and Urology, 2020 (PMID 32257855): Growth hormone secretagogues, including sermorelin-class agents, in body composition management for hypogonadal males
15. FDA, bulk drug substances used in compounding under section 503A: FDA framework describing which bulk substances may be used in 503A compounding, relevant to sermorelin sourcing
16. Drug Testing and Analysis, 2016 (PMID 26456392): Investigation documenting falsified biopharmaceutical injectables circulating in Europe
17. Frontiers in Surgery, 2026 (PMID 42465868): Case report of anterior cervical osteophyte-related dysphagia in a long-term growth hormone user
18. Analytical Biochemistry, 2023 (PMID 37806509): UHPLC-MS/MS method developed for detecting GHRHs in urine samples
19. Journal of Pharmaceutical and Biomedical Analysis, 2022 (PMID 35298973): Antibody-free nanoLC-HRMS/MS assay detecting GHRHs in urine at low picogram-per-milliliter concentrations
20. Analytical and Bioanalytical Chemistry, 2016 (PMID 26879649): Immunoaffinity purification and LC-HRMS/MS method for qualitative identification of GHRHs in human plasma
21. Journal of Mass Spectrometry, 2024 (PMID 38197510): Chromatographic-mass spectrometric analysis of peptidic analytes in doping control urine samples
22. Journal of Chromatography A, 2020 (PMID 32971474): Comparison of magnetic bead surface functionalities for immunopurification of GHRHs before LC-HRMS analysis
23. Drug Testing and Analysis, 2021 (PMID 34665524): Review of advances in detection methods for GHRH synthetic analogs
24. Drug Testing and Analysis, 2015 (PMID 26382721): Expanded test method for peptides over 2 kDa using immunoaffinity purification and LC-HRMS/MS
25. Electrophoresis, 2023 (PMID 36787346): Capillary electrophoresis method developed to separate enantiomeric GHRH analogs
26. Journal of Sports Medicine and Physical Fitness, 2026 (PMID 41880199): Critical review describing growing use of peptide and peptide-analog drugs in recreational and professional sport as a new era of doping